晚期和转移性肾细胞癌- Ain Shams临床肿瘤科经验

Journal of Solid Tumors Pub Date : 2020-02-18 DOI:10.5430/jst.v10n1p18

A. Nagy, M. Kamal, H. Halawani

{"title":"晚期和转移性肾细胞癌- Ain Shams临床肿瘤科经验","authors":"A. Nagy, M. Kamal, H. Halawani","doi":"10.5430/jst.v10n1p18","DOIUrl":null,"url":null,"abstract":"Background: Renal cell carcinoma is a rare tumor and till recently few treatment options were available. It is poorly understood why people develop RCC since only a few etiologic factors have been clinically identified as risk factors for RCC. Purpose: To analyze our experience at Ain Shams University Clinical Oncology department in Egypt with patients presenting with advanced renal cell carcinoma to provide a correlations between clinic-pathological factors, treatment and survival outcomes. Methodology: Retrospective review of the data of 54 patients who were diagnosed as RCC and presented to Ain Shams University Clinical Oncology department in Egypt from 1 May 2013 till 1 May 2015. Descriptive and clinic-pathological data were described using simple and relative frequencies. Survival outcome for the patients will be described using Kaplan Meier curves stratified according to morphology, age group and treatment received. Results: The sample included 54 patients (53.7% were males) of whom 14.3% were less than 40 years and 3.7% were elderly ( ≥ 70 years old). The median age was 55.5 years (SD ± 13.6 , range 19-71). Median PFS was 6.5 months (SD ± 12.3846 Range 43) while the median OS was 13 months (SD ± 12.161 Range 46). PFS in patients aged below 55.5 years was 9 months (95% CI=6.509-11.491) compared to 4 months (95% CI=2.704-5.296) in older patients ( p = .004). PFS in patients who achieved PR after sunitinb was 17 months (95% CI=6.916-27.084) compared to 5 months (95% CI=3.699-6.301) in patients who didn’t achieved PR ( p < .001). OS in patients aged below 55.5 years was 15 months (95% CI=9.131-20.869) compared to 11 months (95% CI=8.947-13.053) in older patients ( p = .012). Favorable pathology status was associated with prolonged OS of 14 months (95% CI= 9.403-18.597) versus 11 months (95% CI=8.363-13.637) for unfavourable pathology status ( p = .11). Low grades histopathogy was associated with prolonged OS of 44 months (95% CI= 38.456-49.544) versus 12 months (95% CI=10.077-13.923) for higher grades ( p = < .001). Conclusion: Multivariate analyses supported a conclusion that younger age was an independent prognostic factor for survival along with other known risk factors such as tumor grade and pathology status.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"188 1","pages":"18"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advanced and metastatic renal cell carcinoma – Ain Shams Clinical Oncology Department Experience\",\"authors\":\"A. Nagy, M. Kamal, H. Halawani\",\"doi\":\"10.5430/jst.v10n1p18\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Renal cell carcinoma is a rare tumor and till recently few treatment options were available. It is poorly understood why people develop RCC since only a few etiologic factors have been clinically identified as risk factors for RCC. Purpose: To analyze our experience at Ain Shams University Clinical Oncology department in Egypt with patients presenting with advanced renal cell carcinoma to provide a correlations between clinic-pathological factors, treatment and survival outcomes. Methodology: Retrospective review of the data of 54 patients who were diagnosed as RCC and presented to Ain Shams University Clinical Oncology department in Egypt from 1 May 2013 till 1 May 2015. Descriptive and clinic-pathological data were described using simple and relative frequencies. Survival outcome for the patients will be described using Kaplan Meier curves stratified according to morphology, age group and treatment received. Results: The sample included 54 patients (53.7% were males) of whom 14.3% were less than 40 years and 3.7% were elderly ( ≥ 70 years old). The median age was 55.5 years (SD ± 13.6 , range 19-71). Median PFS was 6.5 months (SD ± 12.3846 Range 43) while the median OS was 13 months (SD ± 12.161 Range 46). PFS in patients aged below 55.5 years was 9 months (95% CI=6.509-11.491) compared to 4 months (95% CI=2.704-5.296) in older patients ( p = .004). PFS in patients who achieved PR after sunitinb was 17 months (95% CI=6.916-27.084) compared to 5 months (95% CI=3.699-6.301) in patients who didn’t achieved PR ( p < .001). OS in patients aged below 55.5 years was 15 months (95% CI=9.131-20.869) compared to 11 months (95% CI=8.947-13.053) in older patients ( p = .012). Favorable pathology status was associated with prolonged OS of 14 months (95% CI= 9.403-18.597) versus 11 months (95% CI=8.363-13.637) for unfavourable pathology status ( p = .11). Low grades histopathogy was associated with prolonged OS of 44 months (95% CI= 38.456-49.544) versus 12 months (95% CI=10.077-13.923) for higher grades ( p = < .001). Conclusion: Multivariate analyses supported a conclusion that younger age was an independent prognostic factor for survival along with other known risk factors such as tumor grade and pathology status.\",\"PeriodicalId\":17174,\"journal\":{\"name\":\"Journal of Solid Tumors\",\"volume\":\"188 1\",\"pages\":\"18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Solid Tumors\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5430/jst.v10n1p18\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Solid Tumors","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5430/jst.v10n1p18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

背景:肾细胞癌是一种罕见的肿瘤，直到最近才有一些治疗选择。由于临床上只有少数病因被确定为RCC的危险因素，人们对为什么会发生RCC知之甚少。目的:分析我们在埃及艾因沙姆斯大学临床肿瘤科治疗晚期肾细胞癌患者的经验，以提供临床病理因素、治疗和生存结果之间的相关性。方法:回顾性分析2013年5月1日至2015年5月1日在埃及艾因沙姆斯大学临床肿瘤科诊断为RCC的54例患者的资料。描述性和临床病理数据用简单频率和相对频率描述。根据形态学、年龄组和接受的治疗，使用Kaplan Meier曲线对患者的生存结果进行分层。结果:本组54例患者(男性53.7%)，其中40岁以下14.3%，老年人(≥70岁)3.7%。中位年龄为55.5岁(SD±13.6，范围19-71)。中位PFS为6.5个月(SD±12.3846 Range 43)，中位OS为13个月(SD±12.161 Range 46)。55.5岁以下患者的PFS为9个月(95% CI=6.509-11.491)，而老年患者的PFS为4个月(95% CI=2.704-5.296) (p = 0.004)。舒尼替尼治疗后达到PR的患者PFS为17个月(95% CI=6.916-27.084)，而未达到PR的患者PFS为5个月(95% CI=3.699-6.301) (p < 0.001)。55.5岁以下患者的OS为15个月(95% CI=9.131-20.869)，而老年患者的OS为11个月(95% CI=8.947-13.053) (p = 0.012)。病理状态良好的患者生存期延长14个月(95% CI= 9.403-18.597)，病理状态不良的患者生存期延长11个月(95% CI=8.363-13.637) (p = 0.11)。低级别组织病理学与44个月的OS延长相关(95% CI= 38.456-49.544)，而高级别组织病理学与12个月的OS延长相关(95% CI=10.077-13.923) (p = < .001)。结论:多变量分析支持以下结论:年龄较小与其他已知的危险因素(如肿瘤分级和病理状态)一起是生存的独立预后因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advanced and metastatic renal cell carcinoma – Ain Shams Clinical Oncology Department Experience

Background: Renal cell carcinoma is a rare tumor and till recently few treatment options were available. It is poorly understood why people develop RCC since only a few etiologic factors have been clinically identified as risk factors for RCC. Purpose: To analyze our experience at Ain Shams University Clinical Oncology department in Egypt with patients presenting with advanced renal cell carcinoma to provide a correlations between clinic-pathological factors, treatment and survival outcomes. Methodology: Retrospective review of the data of 54 patients who were diagnosed as RCC and presented to Ain Shams University Clinical Oncology department in Egypt from 1 May 2013 till 1 May 2015. Descriptive and clinic-pathological data were described using simple and relative frequencies. Survival outcome for the patients will be described using Kaplan Meier curves stratified according to morphology, age group and treatment received. Results: The sample included 54 patients (53.7% were males) of whom 14.3% were less than 40 years and 3.7% were elderly ( ≥ 70 years old). The median age was 55.5 years (SD ± 13.6 , range 19-71). Median PFS was 6.5 months (SD ± 12.3846 Range 43) while the median OS was 13 months (SD ± 12.161 Range 46). PFS in patients aged below 55.5 years was 9 months (95% CI=6.509-11.491) compared to 4 months (95% CI=2.704-5.296) in older patients ( p = .004). PFS in patients who achieved PR after sunitinb was 17 months (95% CI=6.916-27.084) compared to 5 months (95% CI=3.699-6.301) in patients who didn’t achieved PR ( p < .001). OS in patients aged below 55.5 years was 15 months (95% CI=9.131-20.869) compared to 11 months (95% CI=8.947-13.053) in older patients ( p = .012). Favorable pathology status was associated with prolonged OS of 14 months (95% CI= 9.403-18.597) versus 11 months (95% CI=8.363-13.637) for unfavourable pathology status ( p = .11). Low grades histopathogy was associated with prolonged OS of 44 months (95% CI= 38.456-49.544) versus 12 months (95% CI=10.077-13.923) for higher grades ( p = < .001). Conclusion: Multivariate analyses supported a conclusion that younger age was an independent prognostic factor for survival along with other known risk factors such as tumor grade and pathology status.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Solid Tumors

自引率

0.00%

发文量